More recently, a large cohort study described five glioma groups based on 1p/19q codeletion, IDH1/2 and TERT promoter mutational profile, with important clinical impact, with the “triple-negative” group or the only TERT-mutated group exhibiting a higher mortality risk (Foote et al. 2015; Eckel-Passow et al. 2015). This evidence concerns the gene TERT and glioma.